Kingham T Peter, Pak Linda M, Simpson Amber L, Leung Universe, Doussot Alexandre, D'Angelica Michael I, DeMatteo Ronald P, Allen Peter J, Jarnagin William R
Memorial Sloan Kettering Cancer Center, Department of Surgery, 1275 York Ave, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center, Department of Surgery, 1275 York Ave, New York, NY 10065, USA.
HPB (Oxford). 2018 Mar;20(3):260-267. doi: 10.1016/j.hpb.2017.08.035. Epub 2017 Sep 19.
Neoadjuvant treatment of colorectal liver metastases has become increasingly common, and while effective, often renders small metastases difficult to visualize on intraoperative US. The objective of this study was to determine the utility of a 3D image-guidance system in patients with intraoperative sonographically-occult CRLM.
50 patients with at least one CRLM ≤ 1.5 cm were enrolled in this prospective trial of an FDA-approved Explorer image-guidance system. If the tumor(s) seen on preoperative imaging were not identified with intraoperative US, Explorer was used to target the US examination to the involved area for a more focused assessment. The primary endpoint was the proportion of cases with sonographically-occult metastases identified using Explorer.
Forty-eight patients with preoperative scans within eight weeks of surgery were included for analysis. Forty-six patients were treated with preoperative chemotherapy (median 4 months, range 2-24 months). Overall, 22 sonographically-occult tumors in 14 patients were interrogated by Explorer, of which 15 tumors in 10 patients were located with image-guidance assistance. The only difference between patients with tumors not identified on US and those who did was the number of tumors (median 3 vs. 2, p = 0.018).
3D image-guidance can assist in identifying small CRLM, particularly after treatment with chemotherapy.
ClinicalTrials.gov, NCT02806037, https://clinicaltrials.gov/ct2/show/NCT02806037.
结直肠癌肝转移的新辅助治疗已越来越普遍,尽管有效,但常常使小转移灶在术中超声检查时难以显现。本研究的目的是确定三维图像引导系统在术中超声隐匿性结直肠癌肝转移患者中的应用价值。
50例至少有一个直径≤1.5 cm的结直肠癌肝转移患者纳入了这项关于美国食品药品监督管理局(FDA)批准的探索者图像引导系统的前瞻性试验。如果术前影像学检查发现的肿瘤在术中超声检查时未被识别,则使用探索者系统将超声检查靶向至受累区域进行更有针对性的评估。主要终点是使用探索者系统识别出超声隐匿性转移灶的病例比例。
48例在手术前8周内进行了术前扫描的患者纳入分析。46例患者接受了术前化疗(中位时间4个月,范围2 - 24个月)。总体而言,探索者系统对14例患者中的22个超声隐匿性肿瘤进行了探查,其中在图像引导辅助下定位到了10例患者的15个肿瘤。超声未识别出肿瘤的患者与识别出肿瘤的患者之间唯一的差异是肿瘤数量(中位值分别为3个和2个,p = 0.018)。
三维图像引导可有助于识别小的结直肠癌肝转移灶,尤其是在化疗后。
ClinicalTrials.gov,NCT02806037,https://clinicaltrials.gov/ct2/show/NCT02806037 。